Cadus Pharmaceutical Corp., Sibia enabling technology news

KDUS filed a counterclaim against SIBI in the U.S. District Court for the Southern District of California. SIBI last month sued KDUS, alleging that KDUS is infringing U.S. Patent No. 5,401,629, which covers a drug screening technology (see BioCentury July 15). In the counterclaim, KDUS asserted the invalidity of SIBI's patent and alleged that SIBI engaged in unfair competition and interfered with KDUS's IPO. ...